Schematic illustration of the preparation process of Chimeric VLP vaccine based on fusion protein technology and VPNVax (IMAGE)
Caption
(a) Conventional chimeric VLP vaccine requires first producing fusion viral proteins conjugated with self-assembling modules by challengeable gene design and expression, and then carrying out unpredictable self-assembly of the proteins to get the vaccine particles. (b) VPNVax requires fewer structural design of the viral proteins and could directly apply the production line of subunit proteins. Viral proteins are modified by Traut’s Reagent with part of their amino groups from lysine sites reacted into sulfhydryl groups, followed by post-conjugation onto the surface of the pre-assembly MalPEG-b-PLA nanoparticles through click chemical reactions with maleimide groups. This chemical post-conjugation method is more controllable and efficient.
Credit
©Science China Press
Usage Restrictions
Use with credit.
License
Original content